Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)

OBJECTIVES: To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. METHODS: Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy M, van der Heijde, Désirée, Strand, Vibeke, Atsumi, Tatsuya, McInnes, Iain B, Takeuchi, Tsutomu, Taylor, Peter C, Bracher, Marguerite, Brooks, David, Davies, John, Goode, Christopher, Gupta, Anubha, Mukherjee, Sumanta, O’Shea, Ciara, Saurigny, Didier, Schifano, Lorrie A, Shelton, Celia, Smith, Julia E, Wang, Millie, Wang, Reena, Watts, Sarah, Weinblatt, Michael E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646845/
https://www.ncbi.nlm.nih.gov/pubmed/37699654
http://dx.doi.org/10.1136/ard-2023-224482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646845/
https://www.ncbi.nlm.nih.gov/pubmed/37699654
http://dx.doi.org/10.1136/ard-2023-224482

Ejemplares similares